非小细胞肺癌病人源性NOD/SCID小鼠和BALB/c裸鼠移植瘤模型的建立及比较

doi:10.3969/j.issn.1004-616x.2018.02.007

癌变·畸变·突变 ›› 2018, Vol. 30 ›› Issue (2): 114-119.doi: 10.3969/j.issn.1004-616x.2018.02.007

非小细胞肺癌病人源性NOD/SCID小鼠和BALB/c裸鼠移植瘤模型的建立及比较

吴健彬^1,2, 江妹², 王玥², 许晶², 岳文涛^2,3, 王子彤¹

1. 首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所胸外科, 北京 101149;
2. 首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所细胞生物学研究室, 北京 101149;
3. 首都医科大学附属北京妇产医院中心实验室, 北京 100026

收稿日期:2017-07-03 修回日期:2018-03-16 出版日期:2018-03-30 发布日期:2018-03-30
通讯作者: 岳文涛,E-mail:yuewt@ccmu.edu.cn;王子彤,E-mail:wztdoctor@163.com E-mail:yuewt@ccmu.edu.cn;wztdoctor@163.com
作者简介:吴健彬,E-mail:18810257211@163.com
基金资助:
北京市自然科学基金（7174289）

Comparison of patient-derived non-small cell lung cancer xenegrafts models in NOD/SCID and nude mice

WU Jianbin^1,2, JIANG Mei², WANG Yue², XU Jing², YUE Wentao^2,3, WANG Zitong¹

1. Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149;
2. Department of Cellular and Molecular Biology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149;
3. Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China

Received:2017-07-03 Revised:2018-03-16 Online:2018-03-30 Published:2018-03-30

摘要/Abstract

摘要： 目的：构建人非小细胞肺癌的NOD/SCID小鼠和BALB/c裸鼠移植瘤模型，并探讨移植瘤成瘤性与小鼠品系间的关系，为后续建立优良的动物模型奠定基础。方法：取手术切除获得的23例非小细胞肺癌组织，1 h内移植于NOD/SCID小鼠或BALB/c裸鼠皮下，观察移植瘤成瘤情况，测量移植瘤体积，绘制生长曲线图，计算成瘤率、成瘤潜伏时间和成瘤时间，分析并比较移植成瘤组和未成瘤组所对应患者的相关临床病理指标，并取移植成瘤组和所对应患者的组织标本进行病理学分析。结果：NOD/SCID小鼠皮下移植瘤模型成瘤率（55.6%），BALB/c裸鼠皮下移植瘤模型（20%），两者间差异无统计学意义（P > 0.05），但前者的成瘤潜伏时间和成瘤时间均短于后者（P < 0.05）。患者相关临床病理指标中鳞癌、TNM分期和淋巴结转移情况与移植瘤成瘤建模无明显相关（P=0.109、0.153、0.077），NOD/SCID小鼠和BALB/c裸鼠皮下移植瘤模型均能保持病人肺癌肿瘤组织的形态学特征。结论：成功构建了NOD/SCID小鼠和BALB/c裸鼠皮下移植瘤模型，NOD/SCID小鼠更适宜用于肺癌病人源性皮下移植瘤模型的建立，非小细胞肺癌移植瘤模型的建立为进行体外抗肿瘤药物的筛选提供了良好的研究工具。

关键词: 非小细胞肺癌, 模型, NOD/SCID小鼠, BALB/c裸鼠

Abstract: OBJECTIVE: To establish patient-derived non-small cell lung cancer xenegraft models in NOD/SCID or nude mice,and to compare the tumor-forming rates between these mice. METHODS: Non-small cell lung cancer tissues were collected from 23 patients who underwent surgical resection at the Department of Thoracic Surgery of Beijing Chest Hospital from July 2016 to December 2016. Non-small cell lung cancer tissues were subcutaneously implanted into NOD/SCID mice or BALB/c nude mice within 1 hour after surgical resection. Growth processes of the xenotransplanted tumors were observed,the tumor volumes were measured and the growth curves of the xenotransplanted tumors were plotted. The tumor-forming rates,the tumor latent time and the tumor formatting time were calculated. Then,comparison was made on morphology of patient-derived tumor xenegraft tissue and corresponding primary tumor tissue,and the related patients clinical pathological index of two groups,that could form xenegraft tumor group and couldn't form xenergraft tumor group. RESULTS: Xenegrafts were successfully established (55.6%) in NOD/SCID and (20%) nude mice. The tumor-forming rates of NOD/SCID mice models were higher than the nude mice models,and the tumor latent time (37 d,60 d,P=0.002) and the tumor formatting time (79 d,110 d,P=0.002) had significant differences. Tumor factors might associate with engraftment included squamous histology,TNM stage and the lymph node metastasis. Both mice models could keep the morphology of patient-derived tumor xenegraft tissues. CONCLUSION: The xenotransplantation models of patient-derived non-small cell lung cancer in both NOD/SCID mice and nude mice were successfully established. In comparison with the BALB/c nude mice model,the tumor-forming rates of the NOD/SCID mice model was higher,the tumor latent times and the tumor formatting times were shorter,suggesting that the NOD/SICD mice model was more suitable for the establishment of patient-derived NSCLC xenegraft model.

Key words: NSCLC, model, NOD/SCID mice, BALB/c nude mice

中图分类号:

R73-3

吴健彬, 江妹, 王玥, 许晶, 岳文涛, 王子彤. 非小细胞肺癌病人源性NOD/SCID小鼠和BALB/c裸鼠移植瘤模型的建立及比较[J]. 癌变·畸变·突变, 2018, 30(2): 114-119.

WU Jianbin, JIANG Mei, WANG Yue, XU Jing, YUE Wentao, WANG Zitong. Comparison of patient-derived non-small cell lung cancer xenegrafts models in NOD/SCID and nude mice[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(2): 114-119.

参考文献

[1] TORRE L A,BRAY F,SIEGEL R L,et al. Global cancer statistics,2012[J]. CA Cancer J Clin,2015,65(2):87-108.
[2] CHEN W,ZHENG R,BAADE P D,et al. Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132.
[3] DAY C P,MERLINO G,VAN DYKE T. Preclinical mouse cancer models:a maze of opportunities and challenges[J]. Cell,2015,163(1):39-53.
[4] TENTLER J J,TAN A C,WEEKES C D,et al. Patient-derived tumour xenografts as models for oncology drug development[J]. Nat Rev Clin Oncol,2012,9(6):338-350.
[5] HIDALGO M,AMANT F,BIANKIN A V,et al. Patient-derived xenograft models:an emerging platform for translational cancer research[J]. Cancer Discov,2014,4(9):998-1013.
[6] FICHTNER I,ROLFF J,SOONG R,et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers[J]. Clin Cancer Res,2008,14(20):6456-6468.
[7] JOHN T,KOHLER D,PINTILIE M,et al. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer[J]. Clin Cancer Res,2011,17(1):134-141.
[8] 罗朋. 人肺鳞癌组织在裸鼠体内的移植成瘤性与其Ki-67表达水平的关系[J]. 肿瘤,2014,10(34):913-918.
[9] 卓莹. 荷人肺癌小鼠皮下移植瘤模型的建立及其生物学特性初探[J]. 中国肺癌杂志,2010,6(13):568-574.
[10] NCCN. Clinical Practice Guidelines in Oncology (NCCN Guidelines)[EB/OL]. (2017-07-03). https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
[11] ILIE M,NUNES M,BLOT L,et al. Setting up a wide panel of patient-derived tumor xenografts of non-small cell lung cancer by improving the preanalytical steps[J]. Cancer Med,2015,4(2):201-211.
[12] WANG D,PHAM N A,TONG J,et al. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors[J]. Int J Cancer,2017,140(3):662-673.
[13] 秦川,张连峰,魏泓,等. 实验动物学[M]. 北京:人民卫生出版社,2010:42.

[1]	刘晓霞, 李卫霞, 李志加, 苏镇军, 段晓辉, 韩维文, 王云晓, 贺晓磊, 吕林林, 贾金海. 血清谷胱甘肽过氧化物酶与晚期非小细胞肺癌患者临床病理指标及预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 286-290,295.
[2]	王熙凯, 孟庆贺, 高燕鲁. miR-223-3p通过调控ECT2诱导非小细胞肺癌细胞凋亡的实验研究[J]. 癌变·畸变·突变, 2021, 33(3): 187-192.
[3]	陆雪, 田雪蕾, 赵骅, 蔡恬静, 田梅, 刘青杰. 人外周血淋巴细胞微核分析用于估算离体模拟局部照射剂量的研究[J]. 癌变·畸变·突变, 2021, 33(3): 193-196.
[4]	赵子慧, 王绪华. 非小细胞肺癌伴随诊断的研究进展[J]. 癌变·畸变·突变, 2021, 33(1): 66-71,76.
[5]	刘晓霞, 李卫霞, 苏镇军, 贾金海, 段晓辉, 李志加, 贺晓磊, 吕林林, 刘睿, 王云晓. 晚期非小细胞肺癌病理特征及放化疗联合治疗疗效与患者血清超氧化物歧化酶的关系[J]. 癌变·畸变·突变, 2020, 32(5): 350-354.
[6]	陈昕涛, 王敏君, 严文韬, 孙宇, 杨桃, 朱海英, 胡以平, 陈费. 1型糖尿病动物模型和干细胞治疗的研究进展[J]. 癌变·畸变·突变, 2019, 31(4): 327-330.
[7]	应伟, 王兴远, 江波, 周伟. miR-146a多态性与非小细胞肺癌易感性的研究[J]. 癌变·畸变·突变, 2019, 31(3): 222-226.
[8]	朱嘉微, 胡箫, 王希君, 王雅茹, 冯林, 肖汀. Skp1蛋白在非小细胞肺癌组织和外周血中的表达水平及其临床意义[J]. 癌变·畸变·突变, 2019, 31(2): 89-95.
[9]	毕延伟, 杨小强, 孙平楠, 周小玲. HBV研究模型新进展[J]. 癌变·畸变·突变, 2019, 31(2): 166-170.
[10]	刘颖, 王可, 何杨婷, 肖金荣, 王唤卓, 李旸凯, 魏晟. 基于TCGA数据挖掘筛选肺鳞癌预后相关lncRNA分子标签[J]. 癌变·畸变·突变, 2018, 30(6): 468-472,478.
[11]	林琳, 范潇予, 李恩灿, 凌亚豪, 臧清策, 林生, 贺玖明, 靳洪涛. 小鼠腘窝淋巴结模型评价3种中药注射液的潜在免疫毒性[J]. 癌变·畸变·突变, 2018, 30(4): 275-278,285.
[12]	郭晓, 王蕊, 吴娟, 纪晓坤, 王珩, 张艳, 马阳, 杜芸. 肺腺癌患者新鲜细胞学标本EGFR基因突变检测及意义[J]. 癌变·畸变·突变, 2018, 30(1): 67-70.
[13]	张静, 滕宇, 赵晓婷, 江妹, 岳文涛. Wnt蛋白生成抑制剂2对非小细胞肺癌细胞迁移与侵袭能力的影响[J]. 癌变·畸变·突变, 2017, 29(4): 245-250.
[14]	宋杰, 李萍, 于雪新, 冯林, 高燕宁, 肖汀. Syntenin在非小细胞肺癌中的表达及其与患者总生存期的关系[J]. 癌变·畸变·突变, 2017, 29(2): 102-105.
[15]	丁立新, 解志红, 姜晓燕, 丁库克. 利用微生物吸附放射性核素的研究现状[J]. 癌变·畸变·突变, 2017, 29(1): 74-77.

非小细胞肺癌病人源性NOD/SCID小鼠和BALB/c裸鼠移植瘤模型的建立及比较

Comparison of patient-derived non-small cell lung cancer xenegrafts models in NOD/SCID and nude mice

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价